Lilly reports Phase III BRUIN CLL-322 trial results for Jaypirca combo
The study included 639 patients, 79.8% of whom had previously received covalent BTK inhibitors.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance